This article summarizes recent health news, covering a spectrum of global issues. Highlights include Brazil's avian flu trade ...

Recent health news includes trade restrictions on Brazilian chicken due to bird flu, potential U.S. tariffs on ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

Novo Nordisk said it's ending its collaboration due to concerns with Hims & Hers the company's sales and promotion of cheap knock-offs of the weight loss drug Wegovy, it said on Monday.

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge fund, Parvus Asset Management, building a stake in the company, as ...

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find out why NVO stock is a buy.

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...